|
12-2025
|
A Phase 3, Multicenter, Randomized, Placebo-controlled,
A Phase 3, Multicenter, Randomized, Placebo-controlled,
|
|
02-2024
|
A multi-center, double-blinded and open-label extension
A multi-center, double-blinded and open-label extension
|
|
02-2024
|
An Open-Label Study to Evaluate the Long-Term Safety and
An Open-Label Study to Evaluate the Long-Term Safety and
|
|
11-2023
|
Protocol #QGE031C2302
Protocol #QGE031C2302
|
|
08-2023
|
A Multicentre, Randomised, Double-Blind, Parallel-Group,
A Multicentre, Randomised, Double-Blind, Parallel-Group,
|
|
03-2023
|
Protocol #WA40169
Protocol #WA40169
|
|
01-2023
|
Protocol #GA39855
Protocol #GA39855
|
|
12-2020
|
Protocol #MB29599
Protocol #MB29599
|
|
04-2020
|
Protocol #ML29510
Protocol #ML29510
|
|
01-2020
|
Protocol #TH005
Protocol #TH005
|
|
10-2016
|
Protocol #LAS-MD-45
Protocol #LAS-MD-45
|
|
10-2016
|
Protocol #LAS-MD-45
Protocol #LAS-MD-45
|
|
05-2016
|
Protocol# P05607/001-00
Protocol# P05607/001-00
|
|
05-2016
|
Protocol #A7881013
Protocol #A7881013
|
|
12-2015
|
Protocol#0624-206
Protocol#0624-206
|
|
08-2015
|
Protocol#GB27980
Protocol#GB27980
|
|
07-2015
|
Protocol#LAC-MD-21
Protocol#LAC-MD-21
|
|
04-2015
|
Obesity and Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty Acids
Obesity and Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty Acids
|
|
04-2015
|
Protocol#LAC-MD-36
Protocol#LAC-MD-36
|
|
03-2015
|
Protocol#GB27862
Protocol#GB27862
|
|
03-2015
|
Protocol#FpS-AS-202
Protocol#FpS-AS-202
|
|
03-2015
|
Protocol#FpS-AS-201
Protocol#FpS-AS-201
|
|
12-2014
|
Protocol #LAC-MD-27
Protocol #LAC-MD-27
|
|
12-2014
|
Protocol #LAS-MD-35
Protocol #LAS-MD-35
|
|
11-2014
|
Protocol#LAC-MD-31
Protocol#LAC-MD-31
|
|
09-2014
|
Protocol#ROF-MD-07
Protocol#ROF-MD-07
|
|
09-2014
|
Protocol#LAC-MD-32
Protocol#LAC-MD-32
|
|
07-2014
|
Protocol #LAS-MD-36
Protocol #LAS-MD-36
|
|
03-2014
|
Protocol #LAS-MD-33
Protocol #LAS-MD-33
|
|
06-2013
|
Protocol#0624-203
Protocol#0624-203
|
|
05-2013
|
Protocol #D589BL00003
Protocol #D589BL00003
|
|
09-2012
|
Protocol #COV-2731
Protocol #COV-2731
|
|
06-2012
|
Protocol #P06476
Protocol #P06476
|
|
03-2012
|
Protocol #Q4883G
Protocol #Q4883G
|
|
11-2011
|
Protocol #0624-203
Protocol #0624-203
|
|
10-2011
|
Protocol #205.452
Protocol #205.452
|
|
06-2011
|
SARCA-The Study of Acid Reflux in Children With As
SARCA-The Study of Acid Reflux in Children With As
|
|
06-2011
|
SOYA-The Study of Soy Isoflavones in Asthma
SOYA-The Study of Soy Isoflavones in Asthma
|
|
06-2011
|
Study of Asthma and Nasal Steroids (STAN)
Study of Asthma and Nasal Steroids (STAN)
|
|
01-2011
|
Protocol #091-061
Protocol #091-061
|
|
06-2010
|
SARCA - Study of Acid Reflux in Childhood Asthma
SARCA - Study of Acid Reflux in Childhood Asthma
|
|
06-2010
|
D5899C00001
D5899C00001
|
|
05-2009
|
Repeated Nasal Challenge in Skin Prick Negative Interdermal Positive Dust Mite Patients
Repeated Nasal Challenge in Skin Prick Negative Interdermal Positive Dust Mite Patients
|
|
09-2007
|
Glaxo Smith Kline Protocol #SCO40043
Glaxo Smith Kline Protocol #SCO40043
|
|
07-2007
|
Roche integrin Antagonist Follow-up for Undetected PML
Roche integrin Antagonist Follow-up for Undetected PML
|
|
04-2007
|
CIGE 025/IA05
CIGE 025/IA05
|
|
02-2007
|
Protocol#Q2788g
Protocol#Q2788g
|
|
05-2006
|
A prospective observational study for the psychometric validation of a patient-reported questionnaire in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Protocol OPL104226
A prospective observational study for the psychometric validation of a patient-reported questionnaire in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Protocol OPL104226
|
|
12-2004
|
Role of a Combined Therapy of a Corticosteroid and B2-Agonist in a Murine Model of Allergan and Respiratory Syncytial Virus-Induced Asthma
Role of a Combined Therapy of a Corticosteroid and B2-Agonist in a Murine Model of Allergan and Respiratory Syncytial Virus-Induced Asthma
|
